Novel therapies for rheumatoid arthritis (RA) that target inflammation locally are highly sought after, as such approaches could avoid systemic immunosuppression. To this end, researchers from Hong ...
A drug for autoimmune disease Sjögren's syndrome, picked up by Novartis when it bought MorphoSys for $2.9 billion last year, has hit the target in a pair of phase 3 trials. Ianalumab (VAY736), a drug ...
Otsuka and Vera Therapeutics have both presented new data on drug candidates for IgA nephropathy (IgAN), striving to join a market which is becoming increasingly crowded. Vera Therapeutics reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results